|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1996; 27:1464-1470 © 1996 by the American College of Cardiology Foundation |
Department of Internal Medicine, Section of Cardiology, University of Nebraska Medical Center, Omaha, USA.
OBJECTIVES: The purpose of this study was to examine vasomotor responses mediated by platelets from patients with diabetes mellitus. BACKGROUND: Diabetes mellitus is associated with increased cardiovascular morbidity and mortality, which in part may be due to a variety of abnormalities reported in diabetic platelets. However, the effects of diabetic platelets on vasomotor tone have not been characterized. METHODS: We compared platelet-mediated vasodilation elicited by platelets isolated from 30 healthy volunteers and 29 patients with diabetes mellitus as they were perfused through a preconstricted normal rabbit carotid artery. RESULTS: Platelets from the diabetic patients mediated an impaired dilatory response in comparison with normal platelets: 2.7 +/- 2% versus 15.8 +/- 3.4% (p < 0.001) and 4.1 +/- 2.7% versus 32.7 +/- 3.3% (p < 0.001) (mean +/- SEM) increase in vessel diameter, for 5 X 10(7) and 1 X 10(8) platelets per milliliter perfused, respectively. The degree of impairment was similar for type I (insulin-dependent) and type II (non-insulin-dependent) diabetes mellitus. Normal platelets incubated in high D-glucose concentrations lost their ability to mediate dilation in a concentration-dependent and time-dependent manner. This was not true for incubation of normal platelets in high concentrations of L-glucose or insulin. However, there was not a significant correlation between glucose control in the diabetic patients and the ability of their platelets to mediate vasodilation. CONCLUSIONS: Platelets from patients with diabetes mellitus have an impaired ability to mediate vasodilation. This impairment appears to be mediated by high glucose concentration. Further work is needed to elucidate the mechanisms for this abnormality in diabetic platelets.
This article has been cited by other articles:
|
|
 |
|
  P. Rousseau, M. Tartas, B. Fromy, A. Godon, M.-A. Custaud, J. L. Saumet, and P. Abraham Platelet inhibition by low-dose aspirin but not by clopidogrel reduces the axon-reflex current-induced vasodilation in humans Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1420 - R1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tartas, P. Bouye, A. Koitka, V. Jaquinandi, L. Tan, J. L. Saumet, and P. Abraham Cathodal current-induced vasodilation to single application and the amplified response to repeated application in humans rely on aspirin-sensitive mechanisms J Appl Physiol, October 1, 2005; 99(4): 1538 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsuno, H. Tokuda, A. Ishisaki, Y. Zhou, Y. Kitajima, and O. Kozawa P2Y12 Receptors Play a Significant Role in the Development of Platelet Microaggregation in Patients with Diabetes J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Theroux, J. Alexander Jr, C. Pharand, E. Barr, S. Snapinn, A. F. Ghannam, and F. L. Sax Glycoprotein IIb/IIIa Receptor Blockade Improves Outcomes in Diabetic Patients Presenting With Unstable Angina/Non-ST-Elevation Myocardial Infarction : Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Circulation, November 14, 2000; 102(20): 2466 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shechter, C. N. Bairey Merz, M. J. Paul-Labrador, and S. Kaul Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease J. Am. Coll. Cardiol., February 1, 2000; 35(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, K. Kottke-Marchant, D. J. Moliterno, M. L. Rosenthal, N. K. Godfrey, B. S. Coller, E. J. Topol, and A. M. Lincoff Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention Circulation, November 9, 1999; 100(19): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Abizaid, G. S. Mintz, A. Abizaid, R. Mehran, A. J. Lansky, A. D. Pichard, L. F. Satler, H. Wu, K. M. Kent, and M. B. Leon One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms J. Am. Coll. Cardiol., September 1, 1999; 34(3): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Abizaid, G. S. Mintz, R. Mehran, A. Abizaid, A. J. Lansky, A. D. Pichard, L. F. Satler, H. Wu, C. Pappas, K. M. Kent, et al. Long-Term Follow-Up After Percutaneous Transluminal Coronary Angioplasty Was Not Performed Based on Intravascular Ultrasound Findings : Importance of Lumen Dimensions Circulation, July 20, 1999; 100(3): 256 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Oskarsson, T. G. Hofmeyer, and M. T. Olivari Cyclosporine Impairs the Ability of Human Platelets to Mediate Vasodilation Hypertension, June 1, 1997; 29(6): 1314 - 1321. [Abstract] [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
